Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial—Correction

Incorrect Numbers. The Original Contribution entitled "Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial" published in the April 4, 2001, issue of THE JOURNAL (2001;285:1711-1718) contained some incorrect numbers. On page 1715, in the first full paragraph in column 1, the third and fourth sentences should be replaced with: "Among patents who had baseline LDL cholesterol levels of less than or equal to the median value of 121 mg/dL (3.1 mmol/L), primary end point events occurred in 113 (15.0%) of 752 patients in the atorvastatin group and 136 (18.7%) of 729 patients in the placebo group (RR, 0.77; 95% CI, 0.59-0.98). Among patients who had baseline LDL cholesterol levels greater than the median value, primary end point events occurred in 109 (15.0%) of 726 patients in the atorvastatin group and 124 (16.6%) of 749 patients in the placebo group (RR, 0.92; 95% CI, 0.71-1.19). One hundred thirty patients did not have a complete set of baseline lipid measurements by the central laboratory and are not included in this analysis."